Innocare Pharma
Innocare Pharma, a leading biopharmaceutical company headquartered in China (CN), is dedicated to advancing innovative therapies in the oncology and autoimmune disease sectors. Founded in 2015, the company has rapidly established itself as a key player in the industry, focusing on the development of novel treatments that address unmet medical needs. With a robust pipeline of targeted therapies and monoclonal antibodies, Innocare Pharma distinguishes itself through its commitment to research and development, leveraging cutting-edge technology to enhance patient outcomes. The company has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position in the global market. As Innocare Pharma continues to expand its operational reach, it remains focused on delivering high-quality, effective solutions that improve the lives of patients worldwide.
DitchCarbon Score
How does Innocare Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Innocare Pharma's score of 24 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Innocare Pharma's reported carbon emissions
Innocare Pharma, headquartered in China (CN), reported significant carbon emissions in recent years. In 2023, the company emitted approximately 12,114,590 kg CO2e, with Scope 1 emissions accounting for about 19,950 kg CO2e and Scope 2 emissions comprising the majority at approximately 12,094,640 kg CO2e. This marked an increase from 2022, where total emissions were about 9,835,800 kg CO2e, all from Scope 2. In 2021, Innocare Pharma's emissions reached approximately 9,236,400 kg CO2e, again solely from Scope 2, while in 2020, the total emissions were about 2,476,590 kg CO2e, entirely from Scope 2 as well. The company has not disclosed any specific reduction targets or initiatives as part of its climate commitments, indicating a potential area for future focus in sustainability efforts. Overall, Innocare Pharma's emissions data highlights a trend of increasing carbon output, primarily from energy consumption, underscoring the need for enhanced climate strategies moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | 00,000 |
| Scope 2 | 2,476,590 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Innocare Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
